These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8504997)

  • 1. An unusual evolution of the serum CA 125 level in a ovarian cancer patient.
    Huys J; Vereecke C; De Sutter L; Troch M
    Gynecol Oncol; 1993 May; 49(2):259-61. PubMed ID: 8504997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA 125 in ovarian cancer.
    van der Burg ME; Lammes FB; Verweij J
    Neth J Med; 1992 Feb; 40(1-2):36-51. PubMed ID: 1579185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of serum CA 125 levels in the monitoring of ovarian cancer.
    Vergote IB; Børmer OP; Abeler VM
    Am J Obstet Gynecol; 1987 Jul; 157(1):88-92. PubMed ID: 2440307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between serum CA125 level and second-look findings in ovarian cancers].
    Liu LY
    Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):287-9. PubMed ID: 1327702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of CA 125 as a marker of ovarian cancer.
    Markowska J; Manys G; Kubaszewska M
    Eur J Gynaecol Oncol; 1992; 13(4):360-5. PubMed ID: 1516589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer.
    Makar AP; Kristensen GB; Børmer OP; Tropé CG
    Gynecol Oncol; 1992 Jun; 45(3):323-8. PubMed ID: 1612511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary.
    van der Burg ME; Lammes FB; Verweij J
    Surg Gynecol Obstet; 1993 Apr; 176(4):310-4. PubMed ID: 8460404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA-125 monitoring in the management of ovarian cancer.
    Bruzzone M; Onetto M; Campora E; Chiara S; Oliva C; Guido T; Merlini L; Parodi S; Bentivoglio G; Ventrella W
    Anticancer Res; 1990; 10(5A):1353-9. PubMed ID: 2241112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-associated antigen CA 125 in patients with ovarian cancer.
    Heinonen PK; Tontti K; Koivula T; Pystynen P
    Br J Obstet Gynaecol; 1985 May; 92(5):528-31. PubMed ID: 3857939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA 125 in monitoring clinical course in ovarian cancer patients. A prospective clinical study.
    Markowska J; Manys G; Szewierski Z
    Eur J Gynaecol Oncol; 1992; 13(2):201-4. PubMed ID: 1587296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness and false-positive results of CA 125 as a tumor marker of ovarian cancer--a study on 674 patients.
    Takahashi K; Shibukawa T; Moriyama M; Shirai T; Kijima S; Iwanari O; Matsunaga I; Kitao M
    Jpn J Surg; 1986 Sep; 16(5):305-10. PubMed ID: 3467109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical significance of pre-operative serum CA 125 in ovarian cancer.
    Cruickshank DJ; Fullerton WT; Klopper A
    Br J Obstet Gynaecol; 1987 Jul; 94(7):692-5. PubMed ID: 2441738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
    Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A
    Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
    Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
    J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.
    Gallion HH; Hunter JE; van Nagell JR; Averette HE; Cain JM; Copeland LJ; Higgins RV; Husseinzadeh N; Nahhas WA; Partridge EE
    Gynecol Oncol; 1992 Jul; 46(1):29-32. PubMed ID: 1634137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA-125 values predictive of clinical response during second-line chemotherapy for epithelial ovarian cancer.
    Ng LW; Homesley HD; Barrett RJ; Welander CE; Case LD
    Am J Clin Oncol; 1989 Apr; 12(2):106-9. PubMed ID: 2705398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of second-look laparotomy for ovarian cancer: second-look vs. serum CA125.
    Liu L; Hong W; Hou Y; Yao Z; Wu A; Wang X
    Chin Med Sci J; 1991 Jun; 6(2):96-9. PubMed ID: 1804384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated CA 125 serum levels and epithelial ovarian cancer metastatic to retroperitoneal lymph nodes.
    Finkler NJ; Kapnick SJ; Griffiths CT; Knapp RC
    Gynecol Oncol; 1988 Mar; 29(3):356-60. PubMed ID: 3162223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of CA 125 in advanced ovarian cancer.
    Mogensen O
    Gynecol Oncol; 1992 Mar; 44(3):207-12. PubMed ID: 1541430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA125 in peritoneal fluid of ovarian cancer patients.
    Vergote IB; Onsrud M; Børmer OP; Sert BM; Moen M
    Gynecol Oncol; 1992 Feb; 44(2):161-5. PubMed ID: 1544593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.